{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:00:12Z","timestamp":1790614812245,"version":"4.1.0"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Atopic dermatitis (AD) is a chronic inflammatory skin disease involving Th2 cytokine-driven inflammation. AD patients are at risk of developing conjunctivitis, including atopic keratoconjunctivitis (AKC), a sight-threatening chronic allergic eye disease involving both Th2 and Th1\/17 cytokine-driven inflammation.<\/jats:p>\n            <jats:p>In AD, dupilumab is highly effective by inhibiting interleukin (IL)-4 and IL-13. However, some AD patients develop dupilumab-associated ocular surface disease (DAOSD), an AKC-like disease. There are no biomarkers to predict who will develop DAOSD. The purpose of this review is to highlight recent findings in AD and AKC suggesting different immunopathogenic mechanisms are involved.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>A recent proteomics study of tear fluids identified raised inflammatory markers (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a31) in AD patients with DAOSD (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a22) and a shift towards a Th1\/17 profile. Alternative biologics have been investigated for treating moderate-to-severe AD which have fewer ocular side-effects. The inhibitory effects of dupilumab cause an associated upregulation of IL-33 which could lead to an AKC-like disease. A recent therapeutic approach in AD via regulatory T cells suggests a novel treatment for those at risk of DAOSD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Ocular side-effects of dupilumab suggest that the immunopathogenic pathways in moderate-to-severe AD and AKC are not the same and, for DAOSD, might require different treatment approaches.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aci.0000000000001102","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T12:03:42Z","timestamp":1754481822000},"page":"388-394","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Emerging concepts in atopic dermatitis and atopic keratoconjunctivitis"],"prefix":"10.1097","volume":"25","author":[{"given":"Keya","family":"Jafari","sequence":"first","affiliation":[{"name":"UCL Institute of Ophthalmology"},{"name":"Biomedical Research Centre, UCL & Moorfields Eye Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia L.","family":"Calder","sequence":"additional","affiliation":[{"name":"UCL Institute of Ophthalmology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"R1-20250829","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0091-6749(97)70279-3","article-title":"T-cell cytokines in chronic allergic eye disease","volume":"100","author":"Metz","year":"1997","journal-title":"J Allergy Clin Immunol"},{"key":"R2-20250829","first-page":"1","article-title":"Type 2 inflammation and its role in dermatologic disease","volume":"0","author":"Chovatiya","year":"2025","journal-title":"Int J Dermatol"},{"key":"R3-20250829","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40257-019-00455-5","article-title":"Ocular co-morbidities of atopic dermatitis","volume":"20","author":"Beck","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"R4-20250829","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1046\/j.1365-2222.1999.00585.x","article-title":"Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease","volume":"29","author":"Calder","year":"1999","journal-title":"Clin Exp Allergy"},{"key":"R5-20250829","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0161-6420(98)99043-1","article-title":"A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis","volume":"105","author":"Hingorani","year":"1998","journal-title":"Ophthalmol"},{"key":"R6-20250829","first-page":"6917185","article-title":"The role of Th17 cells and IL-17 in Th2 immune responses of allergic conjunctivitis","volume":"1","author":"Meng","year":"2020","journal-title":"J Ophthalmol"},{"key":"R7-20250829","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ajoc.2017.06.017","article-title":"Cicatricial ectropion in a patient treated with dupilumab","volume":"7","author":"Barnes","year":"2017","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R8-20250829","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/jamadermatol.2018.3427","article-title":"Cicatrizing blepharoconjunctivitis occurring during dupilumab treatment and a proposed algorithm for its management","volume":"154","author":"Levine","year":"2018","journal-title":"JAMA Dermatol"},{"key":"R9-20250829","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/ICO.0000000000002262","article-title":"Dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"39","author":"Liberman","year":"2020","journal-title":"Cornea"},{"key":"R10-20250829","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40123-019-0191-9","article-title":"Ocular surface diseases induced by dupilumab in severe atopic dermatitis","volume":"8","author":"Maudinet","year":"2019","journal-title":"Ophthalmol Ther"},{"key":"R11-20250829","doi-asserted-by":"crossref","first-page":"100550","DOI":"10.1016\/j.ajoc.2019.100550","article-title":"Dupilumab-associated blepharoconjunctivitis","volume":"16","author":"Paulose","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R12-20250829","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1038\/s41433-020-01379-9","article-title":"Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae","volume":"35","author":"Popiela","year":"2021","journal-title":"Eye (Lond)"},{"key":"R13-20250829","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1080\/09273948.2018.1533567","article-title":"Dupilumab-induced follicular conjunctivitis","volume":"27","author":"Shen","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"R14-20250829","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/01676830.2018.1553190","article-title":"Two differing presentations of periocular dermatitis as a side effect of dupilumab for atopic dermatitis","volume":"38","author":"Yamane","year":"2019","journal-title":"Orbit"},{"key":"R15-20250829","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"R16-20250829","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","article-title":"Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9)","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"R17-20250829","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/bjophthalmol-2019-315010","article-title":"Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment","volume":"104","author":"Nahum","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R18-20250829","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/bjd.17538","article-title":"Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis","volume":"180","author":"Bakker","year":"2019","journal-title":"Br J Dermatol"},{"key":"R19-20250829","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"R20-20250829","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40257-020-00527-x","article-title":"Dupilumab provides favourable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis","volume":"21","author":"Beck","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"R21-20250829","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"R22-20250829","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"R23-20250829","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"R24-20250829","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"R25-20250829","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","article-title":"Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"154","author":"Treister","year":"2018","journal-title":"JAMA Dermatol"},{"key":"R26-20250829","doi-asserted-by":"crossref","first-page":"adv00666","DOI":"10.2340\/actadv.v102.1128","article-title":"Identification of risk factors for dupilumab-associated ocular surface disease in patients with atopic dermatitis","volume":"102","author":"Achten","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"R27-20250829","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/jdv.18932","article-title":"Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients","volume":"37","author":"Costedoat","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R28-20250829","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.alit.2023.12.001","article-title":"Exploring patient background and biomarkers associated with the development of dupilumab-associated conjunctivitis and blepharitis","volume":"73","author":"Kido-Nakahara","year":"2024","journal-title":"Allergol Int"},{"key":"R29-20250829","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.alit.2022.09.005","article-title":"Biologics for allergy: therapeutic potential for ocular allergic diseases and adverse effects on the eye","volume":"72","author":"Fukuda","year":"2023","journal-title":"Allergol Int"},{"key":"R30-20250829","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s12016-022-08934-0","article-title":"Dupilumab-associated adverse events during treatment of allergic diseases","volume":"62","author":"Kychygina","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"R31-20250829","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1165\/rcmb.2003-0331OC","article-title":"Endothelin-1 inhibits mucin secretion from ovine airway epithelial goblet cells","volume":"31","author":"Clancy","year":"2004","journal-title":"Am J Respir Cell Mol Biol"},{"key":"R32-20250829","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/cea.70025","article-title":"Dupilumab-associated ocular surface disease in paediatric atopic dermatitis patients: results from the BioDay Registry","volume":"55","author":"van der Rijst","year":"2025","journal-title":"Clin Exp Allergy"},{"key":"R33-20250829","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1136\/bjo.2009.173419","article-title":"Expression of the interleukin-4 receptor \u03b1 in human conjunctival epithelial cells","volume":"94","author":"Ueta","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"R34-20250829","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1167\/iovs.14-15496","article-title":"IL-13 stimulates proliferation and expression of mucin and immunomodulatory genes in cultured conjunctival goblet cells","volume":"56","author":"Tukler Henriksson","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R35-20250829","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaad.2021.09.029","article-title":"Dupilumab-induced ocular surface disease: a systematic review","volume":"86","author":"Fachler","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"R36-20250829","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/exd.14859","article-title":"Dupilumab-associated ocular adverse events are predicted by low tear breakup time and correlate with high IL-33 tear concentrations in patients with atopic dermatitis","volume":"32","author":"Chiricozzi","year":"2023","journal-title":"Exp Dermatol"},{"key":"R37-20250829","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/all.16412","article-title":"Comparison of CD30L and OX40L reveals CD30L as a promising therapeutic target in atopic dermatitis","volume":"80","author":"Gupta","year":"2024","journal-title":"Allergy"},{"key":"R38-20250829","first-page":"1","article-title":"Dupilumab-associated ocular surface disease is characterized by a shift from Th2\/Th17 toward Th1\/Th17 inflammation","volume":"00","author":"Thormann","year":"2023","journal-title":"Allergy"},{"key":"R39-20250829","first-page":"e354","article-title":"Dupilumab-associated ocular surface disease or atopic keratoconjunctivitis not improved by dupilumab? Upadacitinib may clarify the dilemma: a case report","volume":"e354","author":"Galluzzo","year":"2024","journal-title":"Skin Health and Dis"},{"key":"R40-20250829","first-page":"278","article-title":"Demodex musculi infestation in genetically immunomodulated mice","volume":"66","author":"Smith","year":"2016","journal-title":"Comp Med"},{"key":"R41-20250829","doi-asserted-by":"crossref","first-page":"405","DOI":"10.5114\/ada.2017.71105","article-title":"The role of regulatory T cells and genes involved in their differentiation in pathogenesis of selected inflammatory and neoplastic skin diseases. Part II: the Treg role in skin disease patogenesis","volume":"34","author":"Nedoszytko","year":"2017","journal-title":"Postepy Dermatol Allergol"},{"key":"R42-20250829","doi-asserted-by":"crossref","first-page":"9230","DOI":"10.1038\/s41467-024-53384-1","article-title":"The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials","volume":"15","author":"Silverberg","year":"2024","journal-title":"Nat Commun"},{"key":"R43-20250829","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/ACI.0b013e32833e16e4","article-title":"Atopic keratoconjunctivitis and atopic dermatitis","volume":"10","author":"Guglielmetti","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R44-20250829","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2017.03.003","article-title":"Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis","volume":"77","author":"Thyssen","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R45-20250829","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0161-6420(91)32322-4","article-title":"Clinical features of atopic keratoconjunctivitis","volume":"98","author":"Tuft","year":"1991","journal-title":"Ophthalmology"},{"key":"R46-20250829","doi-asserted-by":"crossref","first-page":"100361","DOI":"10.1016\/j.xjidi.2025.100361","article-title":"Metabolomic and lipidomic alterations in patients with atopic dermatitis with dupilumab-associated ocular surface disease","volume":"5","author":"Patra","year":"2025","journal-title":"JID Innov"},{"key":"R47-20250829","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1080\/02713683.2022.2110597","article-title":"Tear film miRNAs and their association with human dry eye disease","volume":"47","author":"Pucker","year":"2022","journal-title":"Curr Eye Res"},{"key":"R48-20250829","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jtos.2025.05.001","article-title":"Tear fluid derived extracellular vesicles for new biomarker discovery","volume":"37","author":"Phan","year":"2025","journal-title":"Ocul Surf"},{"key":"R49-20250829","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1111\/jdv.20233","article-title":"Evolution of dupilumab-associated conjunctivitis in patients with atopic dermatitis after switching dupilumab to tralokinumab or Janus kinase inhibitors (RESO-ADOC study)","volume":"38","author":"Reguiai","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R50-20250829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/03007995.2024.2436982","article-title":"Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomised clinical trial (ADhere-J)","volume":"41","author":"Katoh","year":"2025","journal-title":"Curr Med Res Opin"},{"key":"R51-20250829","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","article-title":"Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA1 and ARCADIA2): results from two replicate, double-blind, randomised controlled phase 3 trials","volume":"404","author":"Silverberg","year":"2024","journal-title":"Lancet"},{"key":"R52-20250829","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.3390\/jcm13133818","article-title":"Impact of Upadacitinib on atopic keratoconjunctivitis exacerbated by dupilumab treatment in atopic dermatitis patients: a prospective dermatological and ophthalmological clinical evaluation in common clinical practice","volume":"13","author":"Paganini","year":"2024","journal-title":"J Clin Med"},{"key":"R53-20250829","doi-asserted-by":"crossref","first-page":"100323","DOI":"10.1016\/j.jacig.2024.100323","article-title":"Successful treatment of the dupilumab-induced psoriatic dermatitis\/arthritis and atopic dermatitis with a JAK inhibitor: a case report and literature review","volume":"3","author":"Tsunoda","year":"2024","journal-title":"J Allergy Clin Immunol Global"}],"container-title":["Current Opinion in Allergy &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ACI.0000000000001102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T16:00:22Z","timestamp":1756483222000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ACI.0000000000001102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/aci.0000000000001102","relation":{},"ISSN":["1473-6322"],"issn-type":[{"value":"1473-6322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]}}}